Testosterone Therapy

The cardiovascular fear that defined twenty years of testosterone prescribing has collapsed under one large trial — but the evidence that remains is narrower than the clinics selling "optimization" suggest: testosterone reliably treats genuine, symptomatic deficiency, yet it is not a longevity drug or a tune-up for healthy men.

Testosterone replacement therapy (TRT) has lived under a heavier regulatory cloud than almost any drug in routine internal medicine — a 2015 FDA warning, added to every testosterone label, about a possible increased risk of heart attack and stroke, retrospective signals of acute harm, and observational data linking low endogenous testosterone to higher mortality — though in the largest pooled analysis of community cohorts higher all-cause mortality was seen in men below about 7.4 nmol/L (213 ng/dL), a level well under the usual diagnostic thresholds.[1] The 2023–2026 evidence has reorganized the picture. The TRAVERSE trial settled the cardiovascular question prospectively. A 737-man treatment registry reported an extraordinary — but, on inspection, non-credible — mortality reduction in the men with the most to lose. A genetic study using lifelong-exposure data flagged a subtler hypertensive risk that clinical trials are too short to see. None of these alone tells the whole story; together they sketch a calibrated answer to who actually benefits.

What testosterone does, and what "low" means

In adult men testosterone and its metabolites (dihydrotestosterone, estradiol) drive muscle protein synthesis, suppress visceral adiposity, maintain bone mineral density, stimulate erythropoiesis, and support libido, executive cognition, and mood.

Endogenous production falls with age. In the Massachusetts Male Aging Study — a population-based cohort of 1,709 men aged 40–70 at baseline, re-measured 7–10 years later — total testosterone declined 1.6% per year within individuals, with bioavailable testosterone falling 2–3% per year.[2] The Baltimore Longitudinal Study of Aging, following 890 men, quantified how often that decline crosses into deficiency: hypogonadal total-testosterone values were present in about 20% of men over 60, 30% over 70, and 50% over 80.[3]

Three thresholds are in active use, and the spread matters — a man at 320 ng/dL (11.1 nmol/L) is normal by both American criteria and hypogonadal by the European one:

  • AUA: total testosterone <300 ng/dL (10.4 nmol/L) on two separate morning draws plus symptoms.[4]
  • Endocrine Society: <264 ng/dL (9.2 nmol/L) — slightly stricter, more conservative, and anchored to CDC-harmonized assay reference ranges.[5]
  • EAU (European Association of Urology): ≤12 nmol/L (about 346 ng/dL) — the most inclusive of the three, reaffirmed in 2026.[6]

Symptoms of late-onset hypogonadism — fatigue, low libido, poor recovery, mood flatness, lost lean mass — are nonspecific and overlap with poor sleep, alcohol, untreated obstructive sleep apnea (OSA), depression, overtraining, and several common medications. The Endocrine Society puts lifestyle correction first; the AUA asks clinicians to counsel every testosterone-deficient man about lifestyle modification as a treatment strategy, but only as a conditional recommendation, and does not require it before prescribing.[7]

Lifestyle first — endogenous rescue (Moderate)

Before any prescription, the modern guideline path is correction of the inputs that suppress endogenous production:

  • Sleep. In a controlled laboratory study, restricting 10 healthy young men to 5 hours in bed for one week lowered daytime testosterone by 10–15%, with the largest drop in the afternoon and evening.[8] Untreated OSA is a major reversible suppressor — and it causes the same fatigue/low-libido phenotype TRT is often prescribed for. Screen for OSA before pursuing TRT (insomnia-treatment, sleep-breathing).
  • Exercise. 150–300 minutes/week of moderate aerobic activity combined with resistance training reduces visceral fat and improves sexual function; the Endocrine Society puts weight loss and lifestyle correction ahead of pharmacological replacement in obese and metabolically unwell men.[9] See resistance-training.
  • Stress and alcohol. Chronic hypercortisolemia suppresses the hypothalamic-pituitary-gonadal (HPG) axis, and heavy alcohol use compounds the suppression. In the Massachusetts Male Aging Study, men in apparent good health — no chronic illness, no prescription medication, no obesity, no excessive drinking — carried androgen levels 10–15% higher than the cohort as a whole at the same age.[10]
  • Endocrine-disrupting chemicals. Phthalates, bisphenols, and parabens depress sex hormone-binding globulin (SHBG) and disrupt androgen signalling; a five-day French intervention in which 103 women swapped their usual personal-care products for alternatives free of the chemicals of interest cut urinary phenoxyacetic acid by about 64%, bisphenol A by about 39% and methylparaben by about 30%.[11] Those are exposure biomarkers in young women, not testosterone in men — the relevance here is that the exposure is quickly modifiable, not that swapping shampoo raises testosterone. See environmental-toxins.
  • Varicocele repair (where a clinical varicocele is present) is a structural rather than pharmacological fix. Pooling 48 before-and-after studies, repair raised mean total testosterone by about 82 ng/dL (2.8 nmol/L) over pre-operative levels, after which levels no longer differed significantly from men with no varicocele;[12] in the studies restricted to hypogonadal men the gain was about 114 ng/dL (4.0 nmol/L).[13] This is pooled observational before-and-after data rather than randomised trials, and the men studied were mostly in their late twenties to mid-forties presenting with infertility or sexual dysfunction — so it does not transfer to a 60-year-old with low testosterone and no clinical varicocele.

A meaningful fraction of men presenting as "low T" recover into the normal range after these inputs are corrected. Up to a quarter of men prescribed testosterone never had a testosterone level drawn beforehand — 26.6% of 61,474 US insured men aged 40 and over between 2001 and 2010; only 61% had a baseline prostate-specific antigen (PSA) test.[14] That is a reckless starting point given how many of these substitutes for diagnosis.[15]

Cardiovascular safety — what TRAVERSE settled (Strong)

The defining trial of the field is TRAVERSE — an FDA-mandated, event-driven, double-blind RCT analysing 5,204 men aged 45–80 with documented hypogonadism (two morning T <300 ng/dL plus symptoms) plus either established cardiovascular disease or elevated CV risk, randomized to daily transdermal testosterone gel vs placebo for a mean 21.7 months of treatment with 33 months follow-up.[16]

The primary composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), and non-fatal stroke occurred in 182 men on testosterone (7.0%) vs 190 on placebo (7.3%) — no detectable difference in risk, and formally non-inferior (hazard ratio 0.96, 95% CI 0.78–1.17, against a pre-specified margin of 1.5).[17] Nor was there an excess of prostate cancer — 5 high-grade cancers among 2,596 treated men versus 3 among 2,602 on placebo — or any differential worsening of lower urinary tract symptoms (LUTS), though men entering with a PSA above 3.0 ng/mL, already-severe symptoms, or a prostate nodule were screened out before randomisation, so the reassurance does not extend to them.[18] On 28 February 2025, on the strength of TRAVERSE, the FDA ordered class-wide labeling changes: it required the cardiovascular-risk warning to come off every testosterone label, and cardiovascular language was struck from the boxed warning carried by the oral capsules and the weekly subcutaneous auto-injector — products that then lost that boxed blood-pressure warning outright, between March and July 2025. Boxed warnings did not leave the class, though: the topical gels still open with one about secondary exposure of children to testosterone. In the same action the FDA extended a blood-pressure warning class-wide, after required post-marketing ambulatory studies confirmed a rise across every product — from baseline, about 2 mmHg systolic on the gel, and on the oral capsules from about 2 mmHg (Kyzatrex) to about 5 mmHg (Jatenzo); against placebo in TRAVERSE, a 1.5 mmHg systolic difference at 36 months.[19] The same action deliberately kept the labels' Limitation of Use: safety and efficacy in men with "age-related hypogonadism" have not been established, and testosterone remains approved only for hypogonadism with an identifiable cause. TRAVERSE cleared testosterone of the cardiovascular charge; it did not licence it for age-related decline. The story then moved again: after an expert panel in December 2025, the FDA invited manufacturers on 16 April 2026 to apply for a new indication — low libido in men with idiopathic hypogonadism, meaning low testosterone with no identifiable cause. Nothing has been approved, and an invitation to file is not a decision; the agency was explicit that any new indication "would require demonstration of substantial evidence of effectiveness".[20] It is nonetheless the first regulatory movement toward exactly the population this article argues sits outside the evidence base. The Endocrine Society answered on 16 July 2026 that its 2018 guideline stands, that symptoms alone are not diagnostic, and that terms like "age-related" and "late-onset" hypogonadism "are hard to define operationally and blur the line between treatable disease and normal aging".[21]

The trial's pre-specified diabetes substudy is often misread. In the men with prediabetes, testosterone did not significantly slow progression to diabetes — the rates tracked closely and non-significantly across four years (for example 10.1% vs 14.6% at 24 months; overall P = 0.49), with no improvement in glucose or HbA1c and no diabetes remission in those who already had it.[22] The authors concluded plainly that testosterone alone should not be used to prevent or treat diabetes. The dosing was also conservative, though not in the way it is usually told. Doses were titrated to a target band of 350–750 ng/dL (12.1–26.0 nmol/L), and blood was drawn 24 hours after the gel was applied, so the levels on record are troughs — the trialists' own caveat is that they run below the 24-hour average and below the levels reached in earlier testosterone trials.[23] Mean total testosterone in treated men rose from 220 ng/dL (7.6 nmol/L) at baseline to a post-baseline average of 409 ng/dL (14.2 nmol/L) — inside the target band, but in its lower half.[24] So the trial cannot fully rule out a glycemic effect at higher exposures, but on its hard endpoint the metabolic case for testosterone is not supported.

The opposite result comes from a different trial — and it is the trial the "testosterone prevents diabetes" claim actually traces back to. T4DM randomised 1,007 Australian men aged 50–74 with a large waist, impaired glucose tolerance or new diabetes, and low-normal testosterone but no pathological hypogonadism, all of them already in a structured lifestyle programme, to injected testosterone undecanoate or placebo for two years. Among the 856 men with two-year data, a glucose tolerance test crossed the diabetes threshold in 12% of the testosterone group versus 21% on placebo — about a 41% lower risk (relative risk 0.59, 95% CI 0.43–0.80), a nine-percentage-point absolute difference.[25] Three things kept it from changing practice: a hematocrit safety trigger above 54% fired in 22% of treated men versus 1% on placebo, it has never been replicated, and its funders included the company that markets the study drug. It also tested a different intervention on a different population — a full injected dose in men who were not hypogonadal — so it does not contradict TRAVERSE so much as sit beside it. Metformin and the Ozempic-class drugs remain the better-evidenced way to keep a dysglycemic man from becoming diabetic.

Secondary signals to monitor

TRAVERSE was not unambiguously clean. The testosterone arm showed higher rates of:

  • Atrial fibrillation — 3.5% on testosterone versus 2.4% on placebo, about one extra case per hundred men (P = 0.02). A real arrhythmia signal, important in older men screening for AF — though TRAVERSE was not powered for it and did no protocol ECGs, so atrial fibrillation was captured only as a reported medical event.[26]
  • Acute kidney injury and pulmonary embolism — small absolute increases: acute kidney injury 2.3% versus 1.5%, pulmonary embolism 0.9% versus 0.5%. These come from men aged 45–80 who all had established or high-risk cardiovascular disease, so read them as an upper bound rather than a general-population figure.[27]
  • Fractures — the one signal that runs against expectation. In TRAVERSE's pre-specified fracture subtrial, clinical fractures occurred in 3.5% of men on testosterone versus 2.5% on placebo over a median 3.2 years — about a 43% higher rate (hazard ratio 1.43, 95% CI 1.04–1.97), or roughly one extra fracture per hundred men treated.[28] Most were fall-related rather than the classic osteoporotic sites, and the trial did not measure bone density — but testosterone raising bone mineral density is not the same as testosterone preventing fractures. In the Testosterone Trials bone substudy of older men, testosterone raised spine trabecular volumetric BMD by ~7.5% over a year, with the gain tracking the rise in estradiol somewhat more closely than the rise in testosterone (both correlations significant) — but standard hip scans barely moved and the trial was underpowered for fractures.[29] That fits the male bone physiology: Finkelstein's selective-suppression experiments — healthy men put into temporary gonadal shutdown, then given graded testosterone with or without a drug blocking its conversion to oestrogen — found bone resorption rose as testosterone fell, and rose considerably more when oestrogen production was blocked too; the authors conclude that oestrogens are the primary regulator of bone in adult men, with testosterone contributing.[30] Treat testosterone as a BMD signal, not validated anti-fracture therapy. See bone-density.
  • Elevated blood pressure — confirmed on the ambulatory monitoring the FDA required of every product; since the class-wide labeling action of 28 February 2025, every testosterone product carries a blood-pressure warning.[31]

These belong on the consent conversation, not in the headline.

The Mendelian randomization paradox (Moderate)

The opposite-direction finding came from a 2026 Mendelian randomization (MR = using inherited genetic variants as lifelong-exposure proxies to test causality) study. Genetic instruments derived from more than 425,000 UK Biobank adults of European ancestry were cross-referenced with coronary artery disease (CAD) outcomes from over 1.16 million people in CARDIoGRAMplusC4D.[32] Men with a genetic predisposition to higher lifelong testosterone had a 17% higher CAD risk — an odds ratio of 1.17 (95% CI 1.07–1.27; P = 3.3 × 10⁻⁴), meaning roughly 1.17 times the odds. The effect is small enough that the authors calculate it would take a randomised trial of more than 6,400 men to detect it. (The confidence interval is the range where the true effect most plausibly lies; because this one sits entirely above 1.0, the association is unlikely to be neutral or protective — whereas a range crossing 1.0 would be compatible with no effect.) The signal was null in women (OR 1.01, 95% CI 0.94–1.10).[33] Adjusting for systolic and diastolic blood pressure substantially weakened the association — most of the genetic signal appears to be lifelong hypertensive shear stress, not lipid or inflammatory mechanisms. The broader lesson is that genetic instruments for lifelong testosterone do not reproduce a cardiovascular benefit — the causal signal on hard endpoints runs the wrong way for the "more is better" case that optimization is chasing.

The result looks contradictory next to TRAVERSE but isn't, because the two studies answer different questions. Physiologic replacement in genuinely deficient, symptomatic men — the TRAVERSE population — is not the same intervention as lifelong higher or supraphysiologic exposure, which is what the genetic instrument models. MR captures cumulative exposure from puberty onward; clinical trials capture months-to-years of restoration in older men whose deficiency itself drives visceral adiposity, insulin resistance, and inflammation. Restoring testosterone in a metabolically compromised 60-year-old rescues the dominant short-term killer; lifelong elevated testosterone in an otherwise healthy 30-year-old slowly raises blood pressure for decades.[34] So the MR signal does not overturn the post-TRAVERSE safety story for true hypogonadism; it argues specifically against testosterone "optimization" in eugonadal men.

The take-home: target the middle of the normal range, not the top. Optimization toward 25-year-old physiology in a 55-year-old buys subjective gains at the cost of decades of higher hypertensive load. This is the Wilder pattern again — benefit concentrates in hypogonadal, symptomatic men, while in healthy men the expected value tilts negative.

The mortality registry — a number that doesn't survive scrutiny (Weak)

A 2024 longitudinal registry of 737 men with adult-onset testosterone deficiency, followed for a median of 114 months, reported a hazard ratio of 0.23 (95% CI 0.14–0.40) for all-cause mortality — on its face a 77% lower death rate — with long-acting testosterone undecanoate versus untreated controls — adjusted for age, waist circumference, HbA1c, lipids, blood pressure, smoking, and diabetes.[35]

Do not take that number at face value. A hazard ratio of 0.23 is a 77% reduction in all-cause mortality — a larger effect than statins, smoking cessation, or exercise, from a hormone injection. That is, on its face, implausible, and the study design explains why: this is a non-randomised, unblinded, single-centre registry in which the men who received treatment were the men who chose it, stayed on it, and kept turning up for eleven years of follow-up. That is the textbook setup for healthy-adherer bias (people who adhere to any therapy, including placebo, die less) and immortal-time bias (you cannot be counted as a treated survivor until you have survived long enough to be treated). Multivariable adjustment does not remove either. The same site makes this argument at length about a far more modest effect: in glucosamine, a hazard ratio of 0.85 is shown to be reproducible from selection bias alone, with a true effect of zero. An HR of 0.23 from a weaker design deserves more scepticism, not less.

The decisive comparison is with the randomised evidence. TRAVERSE — 5,204 men, placebo-controlled — found no mortality benefit from testosterone. When a registry and an RCT disagree by that margin, the RCT wins.

What survives is the shape, not the magnitude. In the registry's stratified analysis the apparent survival advantage was concentrated in men with the highest baseline cardiometabolic risk, and near-absent in relatively healthy hypogonadal men — the pattern the authors labelled Wilder's "Law of Initial Value," and the same pattern seen with Ozempic-class drugs: biggest effect in the sickest patients, smallest in healthy adults seeking optimization. That directional finding is consistent with the rest of the evidence base. The 77% figure is not. TRT is a treatment for hypogonadism, not a life-extension lever.

Cognition and mood — no cognitive benefit, little for mood (Moderate)

A 2025 review pooling 13 randomised trials and one observational study reported moderate cognitive gains, but it is not solid enough to tabulate: its abstract and its own results section report different numbers for the same domains, it drops memory as a domain in the results while reporting it in the abstract, and it reports visuospatial performance as significant in one place and non-significant in the other. It also detected significant publication bias — the signature of a literature in which small positive trials are published and small null ones are not — and pooled studies lasting anywhere from five days to three years.[36] The AUA rates the cognitive evidence inconclusive, and that grade tracks the strongest data rather than lagging it. The Testosterone Trials' Cognitive Function Trial randomised 493 men aged 65 and over who had age-associated memory impairment and low testosterone to a year of gel or placebo, and found nothing: delayed paragraph recall differed by −0.07 (95% CI −0.92 to 0.79; P = .88), and every other cognitive point estimate nominally favoured placebo.[37] TRAVERSE, the largest trial in the field, measured cognition too and likewise found no effect, while reporting modest improvements in mood and energy.[38]

Qualitative reviews also report symptom improvement in treatment-resistant depression and mild Alzheimer's.[39] The strongest trial evidence on mood is less encouraging. An individual participant data meta-analysis — one that pools each man's own trial record rather than published summaries — combined 17 placebo-controlled trials in men with low testosterone, median age 67, and found that at 12 months testosterone significantly improved erectile function, overall hypogonadism symptom scores and some quality-of-life measures, but did not significantly improve depressive symptoms.[40] Those men were not selected for depression, so this does not close the question for men who are clinically depressed — but it does mean the mood case rests on small, short trials rather than on the field's largest dataset. For a healthy adult, TRT is not first-line for cognitive complaints; the dementia-prevention levers (hearing, BP, exercise, MIND diet, sleep) outperform on absolute terms.

Epigenetic effects (Weak / preliminary)

The TRIIM trial — 9 men aged 51–65 — used a multi-agent regimen of recombinant human growth hormone, dehydroepiandrosterone (DHEA), and metformin and reported that mean epigenetic age ended about 1.5 years below baseline — which, because a chronological year had also passed, the authors present as a 2.5-year gain relative to no treatment. Those are two quantities, not a range across the four clocks used. Thymic fat-free fraction rose in seven of the nine men.[41] The pilot was uncontrolled and open-label, and testosterone was not part of the regimen, so nothing in it bears on testosterone replacement directly. The authors called for replication in an adequately powered study; the larger TRIIM-X extension has been listed as recruiting since 2020 with no results posted and its own planned completion date now passed.[42]

In population data, higher male testosterone-to-estradiol ratios link to younger PhenoAge and substantially lower DNA methylation-based PAI-1, a biomarker of thrombosis and senescence — a one-SD increase in total T was associated with a 481 pg/mL drop in DNAm PAI-1.[43] See hallmarks-of-aging for the underlying altered intercellular communication hallmark.

An uncontrolled longitudinal cohort — a re-analysis of stored methylation data from 13 trans men and 13 trans women, with no untreated comparison group — found opposite patterns in the first year of gender-affirming hormone therapy. Testosterone in trans men roughly held the pace of aging steady — as measured by DunedinPACE, a DNA-methylation estimate of how fast a person is biologically aging — while slightly shortening methylation-estimated telomere length (p=0.037); feminizing regimens in trans women did the opposite, speeding the pace of aging (p=0.002) with a small telomere gain.[44] Testosterone is a tissue- and sex-specific regulator, not a generic anti-aging molecule.

Female testosterone therapy (Moderate, narrow indication)

Testosterone is a primary female sex steroid; women produce more testosterone than estrogen by mass. The only evidence-based indication for female testosterone therapy is Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women — and the consensus is emphatic that HSDD is diagnosed by full clinical and biopsychosocial assessment, never by a blood testosterone level, for which no diagnostic cutoff exists.[45]

Claims that the case extends beyond libido rest on much weaker evidence than the HSDD indication. The most-cited recent example is a retrospective observational study of 332 women aged 27–78 receiving individualized testosterone through a telehealth platform, in which 84.3% reported improved energy and 89.7% reported improved quality of life.[46] Read those numbers with the design in mind. There was no placebo arm, no blinding, and no baseline symptom score — the outcomes come from a single survey administered after treatment, to women who were still on the drug and had paid for it. Energy, mood, and quality of life are precisely the domains where placebo responses in hormone trials are large, and two of the authors hold a scientific-advisory role with the telehealth provider whose patient data were analysed. The paired biomarker changes are at least objective measurements rather than self-report, but they do not come from the same 332 women: only 120 of them, all drawn from the shortest treatment stratum, were re-tested at 12 weeks, and the authors say they cannot confirm that subgroup represents the cohort. Total testosterone rose about two and a half times, from 16.8 to 42.3 ng/dL (0.58 to 1.47 nmol/L), which mainly confirms the drug was absorbed; triglycerides fell about 13%, with no control group against which to judge that drift. The symptom percentages should be read as hypothesis-generating, not as an effect size. A single-practice retrospective of 100 peri- and post-menopausal women given testosterone pellets over a decade found that the 78 who completed both questionnaires improved in all 11 Menopause Rating Scale categories — but symptoms were measured only twice, at baseline and before the third pellet at roughly six months, and the ten years is the chart-review window, not the follow-up. It is also uncontrolled, side effects occurred in 58 of the 100 women, and two developed breast cancer while on therapy.[47] The global consensus recommends against pellets outright, because they produce supraphysiological concentrations.[48]

The short-term cardiovascular safety profile is reassuring: a 2026 systematic review of 13 randomised trials in 2,628 cisgender women on transdermal testosterone for 8–52 weeks reported no cardiovascular deaths. The same review rated the certainty of long-term evidence low — these are short trials, not lifetime safety data.[49] Dose-dependent androgenic effects (mild acne, hirsutism) are managed by titration or spironolactone.

The biggest current obstacle is supply: in the United States there is no FDA-approved female-specific testosterone formulation. Where none is available, the global consensus explicitly calls off-label prescribing of an approved male formulation "reasonable", provided concentrations stay in the physiological female range and are monitored regularly — it is compounded "bioidentical" testosterone that it advises against, because of the lack of evidence for efficacy and safety rather than dosing variability, except where no authorised equivalent is available.[50] A licensed female-specific product does exist outside the United States — a 1% transdermal cream registered in Australia in 2020 for HSDD in postmenopausal women — and the patch route has already been tried and abandoned, licensed in Europe for surgically menopausal women and then withdrawn. The pressing frontier is US approval of a product that already exists elsewhere, not the invention of a new one.[51]

Diagnostic and monitoring framework (Strong on protocol)

If lifestyle correction has been adequate and symptoms persist with documented biochemical deficiency, the standard protocol is:

Baseline (in addition to the general midlife lab panel):

  • Two fasting morning total testosterone draws (peak production is shortly after waking; a non-fasting draw depresses the measured value and manufactures false-positive low testosterone).
  • SHBG and calculated free testosterone whenever total testosterone sits near the lower limit or SHBG is likely altered — which covers most obese, diabetic and older men.
  • Hematocrit — withhold testosterone if above 50% until the cause is explained; luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, estradiol (if there are breast symptoms or breast enlargement); prostate-specific antigen (PSA) in men over 40.
  • Comprehensive metabolic, lipids (apoB), HbA1c.

Formulation choice (pharmacokinetics differ markedly):

FormulationFrequencyProfileTrade-offs
Cypionate / enanthate IM7–14 dSharp peaks 36–48 h post-dose, troughs by day 14Cheap; precise titration; highest erythrocytosis rate and mood/libido swings
Undecanoate IM (long-acting)Initial, 4 wk, then every 10 wkStable steady state by day 7Most convenient; FDA Risk Evaluation and Mitigation Strategy (REMS) — 30-min post-injection observation for pulmonary oil microembolism (POME) and anaphylaxis
Oral undecanoateTwice daily with foodAbsorbed through the lymphatics, bypassing first-pass liver metabolismNo needles, no skin transfer; absorption depends on taking it with a meal; carries the class blood-pressure warning; not to be confused with the older alkylated oral androgens, which guidelines say never to prescribe; label directs hematocrit checks roughly every 3 months
Enanthate subcutaneous auto-injectorWeekly, self-administeredNarrows the peak-to-trough swing of two-weekly intramuscular dosingAvoids both the intramuscular route and gel transfer; label directs hematocrit checks roughly every 3 months
Transdermal gel (1%, 1.62%, 2%)DailyApproximates circadian profileAvoids injection peaks; transfer risk to women and children on skin contact
Subcutaneous pelletsEvery 3–4 moSteady release after mild initial spikeExcellent compliance; minor surgical procedure; hard to dose-adjust if AE occurs

Sources: [52], [53], and the current FDA prescribing information for the oral and subcutaneous products.

Targets and follow-up:

  • Aim for the middle tertile of the reference range (~450–600 ng/dL, roughly 15.6–20.8 nmol/L), not the top — which is the AUA's own therapeutic target, and happens to align with the genetic finding that lifelong high-normal testosterone carries a hypertensive load.[54]
  • Recheck at 2–4 weeks for gels; at mid-cycle after 3–4 cycles for short-acting IM.
  • Stable phase: every 6–12 months on testosterone, hematocrit, PSA, lipid panel, BP — with hematocrit about every 3 months on the oral capsules and the subcutaneous auto-injector, as their labels direct.
  • Hematocrit of 54% or above is the bright line. Dose reduction is first-line. Lengthening the interval or switching to a gel is reasonable — the guideline's own data put polycythemia at 19% on intramuscular injection, 12.5% on pellets and 5.4% on gels — but if hematocrit stays high while testosterone is only low or normal, that is a hematology referral, not a self-managed phlebotomy.[55] Severe erythrocytosis raises blood viscosity and thrombotic risk.
  • Three-to-six-month efficacy review. If serum normalized but no symptom improvement, discuss cessation.

What's overrated

  • TRT as a generic longevity drug. No mortality benefit has been shown in a randomised trial; the registry's apparent survival advantage, which does not survive scrutiny, was confined to metabolically compromised men with documented deficiency. In healthy eugonadal men the risk-benefit is dominated by HPG-axis suppression (testicular atrophy, infertility) and erythrocytosis.
  • "Optimizing" healthy men into the high-normal range. The MR signal puts a real cost on lifelong elevated testosterone via blood pressure. Aim middle-tertile, not 25-year-old peak.
  • TRT as a libido or energy fix without OSA screening. OSA causes both, suppresses endogenous T directly, and is one of the most cost-effective things to fix in midlife — see sleep-breathing.
  • Compounded female testosterone products. Global consensus advises against them — for lack of efficacy and safety evidence — wherever an approved formulation, including a male one used off-label, is available.
  • The "beyond libido" case for female testosterone. The eye-catching energy and quality-of-life percentages come from uncontrolled, unblinded, industry-linked retrospective cohorts in a symptom domain with a large placebo response. HSDD in postmenopausal women remains the only indication supported by randomised evidence.
  • Starting TRT without a baseline workup. Up to a quarter of men prescribed testosterone never had a level drawn first — they are skipping the easiest reversible causes.

Cautions

  • Fertility loss. Exogenous testosterone suppresses the HPG axis and halts spermatogenesis. Men who want to preserve fertility need a different protocol — human chorionic gonadotropin (hCG), a selective estrogen receptor modulator such as clomiphene, an aromatase inhibitor, or a combination. These are not equivalent: only hCG carries an FDA label for hypogonadotropic hypogonadism in men, clomiphene and aromatase inhibitors are used off-label, and enclomiphene is approved by neither the FDA nor the European regulator, reaching patients only as a compounded product.[56]
  • Polycythemia / erythrocytosis. The single most consistent adverse effect; monitor hematocrit every 6–12 months.
  • Atrial fibrillation, BP elevation, acute kidney injury, pulmonary embolism, and fractures. All real signals from TRAVERSE; relevant for men with baseline risk.
  • Prostate. TRAVERSE found no increase in prostate cancer or worsening LUTS in men without a PSA above 3.0 ng/mL, severe LUTS or a nodule at entry, easing the older fear, but PSA monitoring remains standard of care over age 40.
  • Drug interactions. Opioids, glucocorticoids, and several other common medications suppress endogenous T independently — review the medication list before treating.

Further reading

  • Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). NEJM 2023.[57]
  • Bhasin S et al. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Trial. JAMA Intern Med 2024 — no significant effect on diabetes progression or glycemic control.[58]
  • Mann A et al. Testosterone replacement therapy: association with mortality in high-risk patient subgroups. Andrology 2024.[59]
  • Morbey EJ et al. Higher Circulating Testosterone Linked to Higher CAD Risk in Men: Mendelian Randomization and Survival Analyses. JCEM 2026;111(4):e1029–e1036.[60]
  • Mauvais-Jarvis F. Testosterone and Cardiovascular Disease: The Enduring Myth. JCEM 2026.[61]
  • Wang et al. Effects of androgen replacement therapy on cognitive function: systematic review and meta-analysis. Biomed Rep 2025.[62]
  • Fahy GM et al. Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM). Aging Cell 2019.[63]
  • Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy in Women. JCEM 2019.[64]
  • Feldman HA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002.[65]
  • Harman SM et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men — Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001.[66]
  • Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA 2011.[67]
  • Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018.[68]
  • Elggren CW et al. Testosterone Replacement Therapy in Women Is Associated with Improved Symptom Burden and Favorable Biomarker Changes: A Retrospective Observational Study. J Pers Med 2026 — uncontrolled, unblinded, industry-linked.[69]
  • FDA issues class-wide labeling changes for testosterone products — cardiovascular-risk warning removed, blood-pressure warning extended class-wide, age-related-hypogonadism Limitation of Use retained. 28 February 2025.[70]
  • FDA Takes Step Forward on Testosterone Therapy for Men — 16 April 2026; the FDA invites holders of approved testosterone applications to seek a new indication for low libido in men with idiopathic hypogonadism. Nothing approved.[71]
  • Viana DPDC et al. Cardiovascular mortality associated with testosterone therapy in cisgender women and transgender men: a systematic review. Front Endocrinol 2026.[72]
  • AUA Testosterone Deficiency Guideline.[73]
  • Shoskes JJ et al. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol 2016.[74]

— § —